胰腺癌诊疗规范(2018年版)

2018-12-13 中华人民共和国国家卫生健康委员会 中华人民共和国国家卫生健康委员会官网

胰腺导管腺癌(pancreatic ductal adenocarcinoma)是常见的胰腺肿瘤,恶性程度极高,近年来,发病率在国内外均呈明显的上升趋势。据世界卫生组织(WHO)统计,2012年全球胰腺癌发病率和死亡率分别列恶性肿瘤第13位和第7位。中国国家癌症中心最新统计数据显示,从2000年至2011年中国胰腺癌的发病率增加,2015年我国胰腺癌发病率位居恶性肿瘤中第9位,死亡率位居恶性肿瘤中

中文标题:

胰腺癌诊疗规范(2018年版)

发布日期:

2018-12-13

简要介绍:

胰腺导管腺癌(pancreatic ductal adenocarcinoma)是常见的胰腺肿瘤,恶性程度极高,近年来,发病率在国内外均呈明显的上升趋势。据世界卫生组织(WHO)统计,2012年全球胰腺癌发病率和死亡率分别列恶性肿瘤第13位和第7位。中国国家癌症中心最新统计数据显示,从2000年至2011年中国胰腺癌的发病率增加,2015年我国胰腺癌发病率位居恶性肿瘤中第9位,死亡率位居恶性肿瘤中第6位。 近年来,随着影像、内镜、病理等学科的发展,胰腺癌诊断水平有所提高;外科手术新理念和新技术(如腹腔镜技术、机器人等)的发展,局部治疗手段(如立体定向放疗、纳米刀消融治疗、放射粒子植入等)以及抗肿瘤药物(如吉西他滨、纳米白蛋白紫杉醇、如替吉奥、卡培他滨、伊立替康、奥沙利铂、尼妥珠单抗等)的应用等,为胰腺癌的治疗带来了机遇和进步。 为进一步规范我国胰腺癌诊疗行为,提高医疗机构胰腺癌诊疗水平,改善胰腺癌患者预后,保障医疗质量和医疗安全,特制定本规范。虽然该规范旨在帮助临床决策,但它不能纳入所有可能的临床变化。

拓展指南:胰腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=胰腺癌诊疗规范(2018年版))] GetToolGuiderByIdResponse(projectId=1, id=15da61c001681587, title=胰腺癌诊疗规范(2018年版), enTitle=, guiderFrom=中华人民共和国国家卫生健康委员会官网, authorId=null, author=, summary=胰腺导管腺癌(pancreatic ductal adenocarcinoma)是常见的胰腺肿瘤,恶性程度极高,近年来,发病率在国内外均呈明显的上升趋势。据世界卫生组织(WHO)统计,2012年全球胰腺癌发病率和死亡率分别列恶性肿瘤第13位和第7位。中国国家癌症中心最新统计数据显示,从2000年至2011年中国胰腺癌的发病率增加,2015年我国胰腺癌发病率位居恶性肿瘤中第9位,死亡率位居恶性肿瘤中, cover=, journalId=null, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Thu Dec 13 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>胰腺导管腺癌(pancreatic ductal adenocarcinoma)是常见的胰腺肿瘤,恶性程度极高,近年来,发病率在国内外均呈明显的上升趋势。据世界卫生组织(WHO)统计,2012年全球胰腺癌发病率和死亡率分别列恶性肿瘤第13位和第7位。中国国家癌症中心最新统计数据显示,从2000年至2011年中国胰腺癌的发病率增加,2015年我国胰腺癌发病率位居恶性肿瘤中第9位,死亡率位居恶性肿瘤中第6位。 近年来,随着影像、内镜、病理等学科的发展,胰腺癌诊断水平有所提高;外科手术新理念和新技术(如腹腔镜技术、机器人等)的发展,局部治疗手段(如立体定向放疗、纳米刀消融治疗、放射粒子植入等)以及抗肿瘤药物(如吉西他滨、纳米白蛋白紫杉醇、如替吉奥、卡培他滨、伊立替康、奥沙利铂、尼妥珠单抗等)的应用等,为胰腺癌的治疗带来了机遇和进步。 为进一步规范我国胰腺癌诊疗行为,提高医疗机构胰腺癌诊疗水平,改善胰腺癌患者预后,保障医疗质量和医疗安全,特制定本规范。虽然该规范旨在帮助临床决策,但它不能纳入所有可能的临床变化。</div> <div><br> </div>拓展指南:<strong>与<font color=red>胰腺癌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=e6da81c00166a54f" title="《2018年美国国立综合癌症网络胰腺癌临床实践指南(V2版)》更新要点及临床路径" target=_blank>《2018年美国国立综合癌症网络胰腺癌临床实践指南(V2版)》更新要点及临床路径</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f5add1c0016a207f" title="2018 法国临床实践指南:胰腺癌的诊断,治疗与随访" target=_blank>2018 法国临床实践指南:胰腺癌的诊断,治疗与随访</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e32891c0016190b1" title="胰腺癌综合诊治指南(2018版)外科相关部分解读" target=_blank>胰腺癌综合诊治指南(2018版)外科相关部分解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=77af01c00161e522" title="NCCN临床实践指南:胰腺癌(2018.V2)" target=_blank>NCCN临床实践指南:胰腺癌(2018.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=8a6971c001592eb0" title="胰腺癌综合诊治指南(2018版)" target=_blank>胰腺癌综合诊治指南(2018版)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E8%83%B0%E8%85%BA%E7%99%8C" target=_blank>有关胰腺癌更多指南</a></ul>, tagList=[TagDto(tagId=718, tagName=胰腺癌), TagDto(tagId=540, tagName=诊疗规范)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10329, appHits=912, showAppHits=48, pcHits=7751, showPcHits=2555, likes=103, shares=34, comments=5, approvalStatus=1, publishedTime=Sat Dec 29 00:33:19 CST 2018, publishedTimeString=2018-12-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Dec 29 00:33:19 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 09:47:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=胰腺癌诊疗规范(2018年版))])
胰腺癌诊疗规范(2018年版)
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=952178, encodeId=fc969521e8c3, content=好好学习规范!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcZXiaTBAicoISasIic8SlnIeAst3s2f1Hng3rKqHN1rfOHnutEHyfzFDBYpvZaladia7lHaD1Fp4ABA/132, createdBy=3eaa2459682, createdName=skyline888, createdTime=Mon Mar 29 21:57:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892893, encodeId=a84289289384, content=希望规范能共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLld5O9WkTWqZ2wrpYTLQpC8tZoHU7owCDJlRL5s1aNLozSooYZpnQ940HDibdZ96UoGZIeriasdLAA/132, createdBy=f8be5094257, createdName=ms8476503042947969, createdTime=Sun Oct 18 17:44:34 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882256, encodeId=63a48822563a, content=很好的规范,要好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44412503898, createdName=124a59b0m89暂无昵称, createdTime=Wed Sep 02 20:07:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356944, encodeId=ead2356944e0, content=是该出台规范来指导一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Tue Jan 01 23:15:47 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
    2021-03-29 skyline888

    好好学习规范!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=952178, encodeId=fc969521e8c3, content=好好学习规范!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcZXiaTBAicoISasIic8SlnIeAst3s2f1Hng3rKqHN1rfOHnutEHyfzFDBYpvZaladia7lHaD1Fp4ABA/132, createdBy=3eaa2459682, createdName=skyline888, createdTime=Mon Mar 29 21:57:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892893, encodeId=a84289289384, content=希望规范能共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLld5O9WkTWqZ2wrpYTLQpC8tZoHU7owCDJlRL5s1aNLozSooYZpnQ940HDibdZ96UoGZIeriasdLAA/132, createdBy=f8be5094257, createdName=ms8476503042947969, createdTime=Sun Oct 18 17:44:34 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882256, encodeId=63a48822563a, content=很好的规范,要好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44412503898, createdName=124a59b0m89暂无昵称, createdTime=Wed Sep 02 20:07:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356944, encodeId=ead2356944e0, content=是该出台规范来指导一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Tue Jan 01 23:15:47 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
    2020-10-18 ms8476503042947969

    希望规范能共享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=952178, encodeId=fc969521e8c3, content=好好学习规范!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcZXiaTBAicoISasIic8SlnIeAst3s2f1Hng3rKqHN1rfOHnutEHyfzFDBYpvZaladia7lHaD1Fp4ABA/132, createdBy=3eaa2459682, createdName=skyline888, createdTime=Mon Mar 29 21:57:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892893, encodeId=a84289289384, content=希望规范能共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLld5O9WkTWqZ2wrpYTLQpC8tZoHU7owCDJlRL5s1aNLozSooYZpnQ940HDibdZ96UoGZIeriasdLAA/132, createdBy=f8be5094257, createdName=ms8476503042947969, createdTime=Sun Oct 18 17:44:34 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882256, encodeId=63a48822563a, content=很好的规范,要好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44412503898, createdName=124a59b0m89暂无昵称, createdTime=Wed Sep 02 20:07:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356944, encodeId=ead2356944e0, content=是该出台规范来指导一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Tue Jan 01 23:15:47 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
    2020-09-02 124a59b0m89暂无昵称

    很好的规范,要好好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=952178, encodeId=fc969521e8c3, content=好好学习规范!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcZXiaTBAicoISasIic8SlnIeAst3s2f1Hng3rKqHN1rfOHnutEHyfzFDBYpvZaladia7lHaD1Fp4ABA/132, createdBy=3eaa2459682, createdName=skyline888, createdTime=Mon Mar 29 21:57:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892893, encodeId=a84289289384, content=希望规范能共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLld5O9WkTWqZ2wrpYTLQpC8tZoHU7owCDJlRL5s1aNLozSooYZpnQ940HDibdZ96UoGZIeriasdLAA/132, createdBy=f8be5094257, createdName=ms8476503042947969, createdTime=Sun Oct 18 17:44:34 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882256, encodeId=63a48822563a, content=很好的规范,要好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44412503898, createdName=124a59b0m89暂无昵称, createdTime=Wed Sep 02 20:07:43 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356944, encodeId=ead2356944e0, content=是该出台规范来指导一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc5c2461847, createdName=1405898496_61595865, createdTime=Tue Jan 01 23:15:47 CST 2019, time=2019-01-01, status=1, ipAttribution=)]
    2019-01-01 1405898496_61595865

    是该出台规范来指导一下

    0